Evidence map›Paper›PMID 38740993›Full record

Trial reportNature medicine2024

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

Donna H Ryan, Ildiko Lingvay, John Deanfield, Steven E Kahn, Eric Barros, Bartolome Burguera, Helen M Colhoun, Cintia Cercato, Dror Dicker, Deborah B Horn and 10 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07513168 (Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes), which is not on this map. Cited by 160 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07513168 phase4recruitingstarted 2025, after this paper: background citation

Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial

Ran2025Enrolled60Registered outcomes6Posted comparisons0ConditionsCardiometabolic Risk Factors, Obesity, Weight ReductionArmsLocally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
PMID 33755728PMID 33625476PMID 38679221PMID 36216945PMID 33977495PMID 41773123PMID 31689026PMID 34706925PMID 34942372PMID 35441470PMID 36254579PMID 36578889other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Sleep and obesity-known interactions and open questions.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Review
  17. Review
  18. Review
  19. The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026
    Review
  20. Article

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Donna H RyanPennington Biomedical Research Center, Baton Rouge, LA, USA. ryandh@pbrc.edu.
Ildiko LingvayDepartment of Internal Medicine/Endocrinology and Peter O' Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-7006-7401
John DeanfieldInstitute of Cardiovascular Science, University College London, London, UK.
Steven E KahnVA Puget Sound Health Care System and University of Washington, Seattle, WA, USA.
Eric BarrosNovo Nordisk A/S, Søborg, Denmark.ORCID 0000-0001-6613-4181
Bartolome BurgueraEndocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.
Helen M ColhounInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-8345-3288
Cintia CercatoObesity Unit, Department of Endocrinology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-6181-4951
Dror DickerInternal Medicine Department D, Hasharon Hospital-Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Deborah B HornCenter for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston, TX, USA.
G Kees HovinghNovo Nordisk A/S, Søborg, Denmark.
Ole Kleist JeppesenNovo Nordisk A/S, Søborg, Denmark.
Alexander KokkinosFirst Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
A Michael LincoffDepartment of Cardiovascular Medicine, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0001-8175-2121
Sebastian M MeyhöferInstitute of Endocrinology & Diabetes, University of Lübeck, Lübeck, Germany.
Tugce Kalayci OralNovo Nordisk A/S, Søborg, Denmark.
Jorge PlutzkyCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7194-9876
André P van BeekUniversity of Groningen, University Medical Center Groningen, Department of Endocrinology, Groningen, the Netherlands.ORCID 0000-0002-0335-8177
John P H WildingDepartment of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.ORCID 0000-0003-2839-8404
Robert F KushnerNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m

Indexed as

Body Mass IndexGlucagon-Like PeptidesObesityWeight LossAdultAgedCardiovascular DiseasesDouble-Blind MethodFemaleHumansMaleMiddle AgedSemaglutideTreatment OutcomeGlucagon-Like PeptidesSemaglutide

Identifiers

PMID38740993
PMCPMC11271387

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.